- LLY dividends remain low yield at 0.56 percent but supported by strong earnings growth.
- The next ex dividend date is 13 February 2026 with a quarterly payout of 1.50 dollars per share.
- Powerful revenue and EPS momentum continue to reinforce long term dividend growth capacity.
Dividend Overview
Eli Lilly continues to pair exceptional earnings growth with steady LLY dividends that appeal to long term DRIP investors. The quarterly payout remains 1.50 dollars per share, unchanged from the previous quarter.
This brings the annual total to 6 dollars per share. At a share price near 1,078 dollars, the forward yield sits at 0.56 percent, a common profile for a fast growing pharmaceutical leader.
Dividend growth remains central to Lilly’s appeal. The company has delivered a 5 year dividend CAGR near 15 percent. The next ex dividend date is set for 13 February 2026, with payment scheduled for 10 March.
Market Backdrop
Lilly’s upcoming dividend arrives as the company continues to post standout operational performance. Shares recently surged after management issued a highly upbeat 2026 outlook, with revenue and EPS expectations driving a 9 percent move higher from strong 2026 revenue and EPS guidance.
Momentum continued into earnings season as the stock gapped up following another quarterly beat as shown by the earnings beat. The company also outperformed during broader market volatility, appearing as a notable mover after strong gains in Eli Lilly.
Even brief pullbacks failed to dent the long term story, with short term pressure contrasting with extended strength after the stock fell 7 percent in the session.
For dividend investors focused on stability, this reinforces a key point. Lilly’s growth engine powered by Mounjaro, Zepbound and its metabolic pipeline continues to support reliable dividend expansion even with a modest yield.
Dividend Safety and Payout Capacity
LLY dividends remain well protected by strong earnings and cash flow. With a trailing P E near 53 and meaningful profit increases projected for 2026, the low payout ratio leaves wide room for continued growth.
Margins remain solid and management maintains disciplined capital allocation. Lilly’s Chowder score above 15 stands out for a low yield stock. While no 2026 dividend increase has been announced, the company’s pattern of mid teens growth suggests another raise is likely this year.
Income Perspective
For income focused investors, Lilly’s sub 1 percent yield may prove too light, particularly compared to companies and ETFs yielding 3 percent or more. However, long term dividend growth investors may find the combination of stability and compounding attractive.
Some traders have also explored option based income strategies. Long dated put sales have generated higher implied yields, including premiums on January 2028 contracts offering more than 4 percent annualized returns when selling a 2028 put. This does not replace LLY dividends but highlights added income potential.
Eli Lilly’s February ex dividend date arrives during a period of exceptional business strength. With rapid earnings growth, durable dividends and consistent high teens increases, the company remains one of the most compelling dividend growth stories in the healthcare sector.
